Category Archives: Gene Therapy

Dr Mitchell L. Gaynor author "The Gene Therapy Plan" on "Book Talk" Doug Miles talks with Dr. Mitchell L. Gaynor about his book "The Gene Therapy Plan, Taking Control of Your Genetic Destiny with Diet and Lifestyle". WTMY radio. "Book Talk". By: floralparkkid … Continue reading →

Optimizing mRNA for Gene Therapy Applications: Evaluation of Novel Nucleotide Modifications Here we investigate a series of unusual base modifications in a variety of combinations in both EGFP and Luciferase mRNA. http://www.trilinkbiotech.com/mrna/ Presented at RNA Oligonucleotide... By: TriLink BioTechnologies … Continue reading →

BT1415 - OGM - Gene Therapy By: Sallie Hill Outten … Continue reading →

Gene Therapy Project Description. By: lyirclover22 … Continue reading →

Gene Therapy with LCA https://www.youtube.com/edit?o=U video_id=TkFgQDIqCKw. By: Shannon Price … Continue reading →

Stories of Gene Therapy Biotechnology Project Created By: Dareen Sophie. By: Biotechnology Project … Continue reading →

Spotlight News Spot April 8, 2015 The 6th Annual Wendy Walk for Sarcoma will be held this Sunday, April19 at 10:00 AM.We will meet at the Harmonie Club (4 East 60th Street) for registration and enjoy a beautifulwalkaround Central Park, brunch, and special raffle prizes. You Read More March 26, 2015 Emperor of All Maladies on PBS (CPTV) presented by documentary filmmaker Ken Burns, isbased on the2010 Pulitzer Prize-winning bookThe Emperor of All Maladies: A Biography of Cancerby Dr. Siddhartha Mukherjee. Among other scientists, doctors and patients, the programfeatured ACGT Researcher Read More March 2, 2015 HBO Documentary Series, Vice, aired an episode on February 27th entitled, Killing Cancer, focusing on how different viruses are being used successfully as weapons to target cancer. The program focuses on 2013 ACGT Grantee Dr. John Bell, for his work Read More January 16, 2015 In 2012, Bob Levis, an Allentown, Pennsylvania resident, believed he had come to the end of his life. Diagnosed in 2002 with chronic lymphocytic leukemia, the cancer had resisted every possible treatment and had infiltrated his bone marrow, paralyzing his Read More March 16, 2014 Here is the original post: Alliance for Cancer Gene Therapy (ACGT) Foundation … Continue reading →

New research published online in Blood, the Journal of the American Society of Hematology (ASH), reports that children with "bubble boy disease" who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder -- also known as X-linked severe combined immunodeficiency (SCID-X1) -- receiving the two therapeutic approaches. Children with SCID-X1 are born with a genetic defect that prevents them from developing a normal immune system. Because they are prone to life-threatening infections, infants with SCID-X1 must be kept in a sterile, protective bubble and require extensive treatment for survival beyond infancy. Infants with SCID are most likely to survive if they receive a stem cell transplant from a fully matched donor -- typically a sibling -- a procedure that replaces an infant's diseased stem cells with healthy donor cells. Following a successful fully matched transplant, infants with SCID-X1 are able to produce their own immune cells for the first time. In the absence of a fully matched stem cell donor, infants with SCID-X1 may receive a transplant from a partial, or "half-matched," donor -- typically their … Continue reading →

April 13, 2015 3:37 pm by Meghana Keshavan | 0 Comments MedCity News Cambridge gene therapy startup Voyager Therapeuticsjust wrapped up a $60 million Series B round to advance its treatments for conditions of the CNS like ALS and Parkinsons disease. Voyager is using the money to advance its five clinical and preclinical programs, as well as a platform developed around adeno-associated viruses. New investors include Brookside Capital and Partner Fund Management, with participation from Wellington Management, Casdin Capital and two undisclosed blue chip investment funds. This roundsright on the heels of an impressive $45 million Series A from Third Rock, which was completed just about a year ago as the company launched. Voyagers gene therapiesare in different stages of completion, with its Parkinsons therapy the most advanced: Get our daily newsletter or follow us. Please enter your email below: See the original post here: Cambridge gene therapy startup Voyager Therapeutics raises $60M for CNS disorders … Continue reading →

The Chemistry, Manufacturing and Controls CMC Section of a Gene Therapy IND FDA Presentation for "The Chemistry, Manufacturing and Controls (CMC) Section of a Gene Therapy IND" Other Information - UDI webinar (LIVE) at http://www.globalcomplianceseminar.com - Providing ... By: Chris Leo … Continue reading →